리서치사:Market Glass, Inc. (Formerly Global Industry Analysts, Inc.)
발행일:2025년 08월
페이지 정보:영문 178 Pages
라이선스 & 가격 (부가세 별도)
한글목차
세계의 DNA 및 유전자 클로닝 서비스 시장은 2030년까지 78억 달러에 도달
2024년에 31억 달러로 추정되는 DNA 및 유전자 클로닝 서비스 세계 시장은 2024-2030년간 CAGR 16.5%로 성장하여 2030년에는 78억 달러에 이를 것으로 예측됩니다. 본 보고서에서 분석한 부문 중 하나인 유전자 합성 서비스는 CAGR 18.0%를 나타내고, 분석 기간 종료시에는 37억 달러에 이를 것으로 예측됩니다. 커스텀 클로닝 서비스 분야의 성장률은 분석 기간중 CAGR 13.5%로 추정됩니다.
미국 시장은 8억 2,220만 달러로 추정, 중국은 CAGR 15.4%로 성장 예측
미국의 DNA 및 유전자 클로닝 서비스 시장은 2024년에는 8억 2,220만 달러로 평가되었습니다. 세계 2위 경제대국인 중국은 2030년까지 12억 달러 규모에 이를 것으로 예측되며, 분석 기간인 2024-2030년 CAGR은 15.4%로 추정됩니다. 기타 주목해야 할 지역별 시장으로는 일본과 캐나다가 있으며, 분석 기간중 CAGR은 각각 15.4%와 14.1%를 보일 것으로 예측됩니다. 유럽에서는 독일이 CAGR 11.9%를 보일 전망입니다.
세계의 DNA 및 유전자 클로닝 서비스 시장 - 주요 동향과 촉진요인 정리
합성생물학의 역할 확대로 복제 서비스 수요 증가?
합성생물학은 생명공학, 헬스케어, 산업 분야에서 전례 없는 혁신을 주도하고 변화를 가져올 분야로 급부상하고 있습니다. 이러한 움직임의 중심에는 DNA 및 유전자 복제 서비스가 있으며, 유전 물질을 조작하여 새로운 생물학적 시스템 및 제품을 설계하는 데 필수적인 도구가 되고 있습니다. 맞춤형 유전자 합성, 벡터 구축, 플라스미드 클로닝에 대한 수요 증가는 차세대 치료제, 백신, 진단약, 바이오 소재 개발에서 합성생물학의 응용 확대와 밀접한 관련이 있습니다. 의약품 연구개발에서 유전자 클로닝은 치료용 단백질의 발현, 유전자 기능 연구, 질병 모델 구축에 널리 사용되고 있습니다. 또한, 코로나19 팬데믹을 포함한 최근 세계 보건 동향에 따라 백신 개발을 위한 신속한 유전공학의 중요성이 부각되면서 DNA 및 유전자 복제의 중요성이 부각되고 있습니다. 클로닝 서비스는 연구자들이 특정 DNA 염기서열을 높은 정확도로 복제할 수 있게 해주며, 재조합 단백질이나 단클론 항체를 대규모로 생산하는 데 필수적입니다. 학계, 생명공학 기업, CRO(의약품 개발 수탁기관)의 협력이 진행되면서, 복제 서비스를 고도의 분자생물학적 역량을 갖춘 전문 벤더가 제공하는 아웃소싱의 움직임이 꾸준히 확산되고 있습니다. 이들 업체는 유전자 설계부터 발현 검증까지 통합 솔루션을 제공하여 연구 일정을 간소화하고 기술적 장벽을 낮춥니다. 또한, 복제 키트, 자동화 도구, 온라인 디자인 플랫폼의 등장으로 비전문가 연구실의 접근성이 확대되면서 유전자 편집 기술의 이용이 민주화되고 있습니다. CRISPR-Cas 시스템 및 유전체 공학의 혁신 속도가 빨라지면서 유전자 녹인, 녹아웃, 돌연변이 연구를 지원하는 고충실도 클로닝 서비스에 대한 수요가 더욱 가속화되고 있으며, DNA 및 유전자 클로닝은 생명공학의 미래에 있어 핵심입니다. 생명공학의 미래에 있어 핵심이 되고 있습니다.
기술의 발전은 복제 과정의 효율성과 정확성을 높이고 있는가?
분자생물학 및 유전체학 분야의 기술 발전은 DNA 및 유전자 복제 서비스의 효율성, 정확성, 확장성을 크게 향상시키고 있습니다. 제한효소 및 리가제를 포함한 전통적인 방법은 깁슨 어셈블리, 골든게이트 클로닝, 부위 특이적 돌연변이 유발과 같은 보다 정교한 기술로 진화하여 보다 빠르고 원활한 DNA 어셈블리를 가능하게 하고 있습니다. 이러한 기술은 벡터에 유전자 염기서열을 정확하게 삽입할 수 있고, 복제 오류를 줄이며, 복잡한 유전자 회로를 구축할 수 있습니다. 자동화는 또 다른 큰 변화입니다. 현재 고처리량 로봇 시스템은 반복적인 복제 작업을 놀라운 속도와 재현성으로 수행하여 서비스 제공업체가 빠른 시간 내에 대량의 맞춤형 DNA 구축물을 제공할 수 있게 해주고 있습니다. 실시간 PCR 및 차세대 염기서열 분석(NGS) 검증과 함께 이러한 시스템은 전체 클로닝 워크플로우에 걸쳐 고품질 관리를 보장합니다. 인공지능은 특히 대장균, 효모, 포유류 세포 등 다양한 숙주 생물에서 발현을 위한 유전자 서열 최적화에 있어서도 그 역할이 확대되고 있습니다. AI 알고리즘은 코돈의 사용, mRNA의 구조, GC 함량을 분석하여 번역 효율과 단백질 수율을 향상시킵니다. 또한, 유도성, 다중클론화, 조직 특이적 발현 시스템 개발 등 벡터 설계의 혁신으로 치료, 농업, 산업 각 분야에서 유전자 복제 응용의 범용성이 확대되었습니다. 클라우드 기반 프로젝트 관리 및 LIMS 플랫폼은 고객과 서비스 제공업체 간의 원활한 커뮤니케이션을 가능하게 하여 투명성, 추적성, 데이터 공유를 향상시켰습니다. 이러한 기술적 도약은 연구 성과를 향상시킬 뿐만 아니라, 특히 복제 유전자의 임상 및 상업용 응용 분야에서 연구 기관이 엄격한 규제 및 품질 기준을 충족하는 데 도움이 되고 있습니다. 정밀 생명공학에 대한 수요가 증가함에 따라, 이러한 최첨단 툴의 통합은 DNA 및 유전자 복제 서비스.NET의 새로운 성능 벤치마크를 지속적으로 설정하고 있습니다.
아웃소싱과 커스터마이징으로의 전환은 서비스 제공 모델을 재정의할 것인가?
생명공학 및 제약 연구가 점점 더 복잡해지고 데이터 중심화됨에 따라, 조직들은 개발 기간을 단축하고 전문 지식을 활용하기 위한 전략적 움직임으로 아웃소싱으로 눈을 돌리고 있습니다. DNA 및 유전자 클로닝 서비스는 이러한 아웃소싱 트렌드의 최전선에 있으며, 유전자 합성, 벡터 엔지니어링, 발현 검증, 라이브러리 구축 등의 작업에서 기업들은 외부 파트너를 선호하고 있습니다. 아웃소싱 모델에는 빠른 프로젝트 처리, 전문 인프라에 대한 접근성, 비용 효율성 등 분명한 장점이 있습니다. 주요 서비스 제공업체들은 현재 고도의 맞춤형 솔루션을 제공하고 있으며, 고객은 길이, 서열, 태그, 발현 시스템, 심지어 코돈 최적화 선호도에 따라 유전자 구조물을 지정할 수 있습니다. 이러한 수준의 커스터마이징은 합성 시작 전 유전자 설계, 오류 검사, 최적화를 지원하는 첨단 바이오인포매틱스 플랫폼에 의해 지원됩니다. 또한, 단백질 발현, 정제, 기능 분석과 같은 다운스트림 용도과 서비스가 번들로 제공되는 경우가 많아 엔드 투 엔드 분자생물학적 솔루션을 중앙에서 제공합니다. 복제된 유전자 염기서열은 기술 혁신 파이프라인에 중요한 독점 정보인 경우가 많기 때문에 지적재산권 보호와 기밀 유지가 중요시되고 있습니다. 각 업체들은 블록체인을 활용한 샘플 추적, 시퀀싱 암호화 전송 등 엄격한 데이터 보안 프로토콜을 도입하여 대응하고 있습니다. 특히 중국, 인도 등 아시아태평양에서는 서비스 제공업체들이 품질에 대한 타협 없이 비용 효율적인 선택권을 제공하면서 경쟁과 혁신을 더욱 치열하게 만들고 있습니다. 학술 기관들도 대규모 공동 프로젝트를 위해 복제 서비스를 대규모로 이용하기 위해 상업적 제공업체와 제휴하는 경우가 늘고 있습니다. 이러한 서비스 제공의 변화는 연구 생산성을 최적화할 뿐만 아니라, DNA 및 유전자 클로닝을 보다 광범위한 생명과학 생태계에서 중요한 아웃소싱 유틸리티로 자리매김하고 있습니다.
DNA 및 유전자 복제 서비스 시장을 가속화하는 주요 성장 요인은 무엇인가?
DNA 및 유전자 복제 서비스 시장의 성장은 생명공학 및 생명과학 분야의 기술 발전, 연구의 다양화, 소비자 행동의 변화와 직접적으로 관련된 여러 요인에 의해 주도되고 있습니다. 주요 촉진요인 중 하나는 합성 생물학, 면역 요법, 백신 개발, 농업 생명 공학 및 기타 분야에서 유전자 조사 범위가 확대되고 있으며, 모두 실험 및 치료 용도의 기능적 구조물을 만들기 위해 유전자 복제에 크게 의존하고 있다는 것입니다. CRISPR-Cas9 및 TALEN과 같은 유전자 편집 기술의 광범위한 채택은 질병 모델링이나 기능적 유전자 스크리닝을 위해 유전자 변형을 지원하는 정밀 클로닝 서비스의 필요성을 더욱 증가시키고 있습니다. 이와 함께, 바이오 의약품 파이프라인에서 단일클론항체, 세포 기반 치료제, 재조합 단백질의 부상으로 인해 클로닝을 통해 구축된 신뢰할 수 있는 발현 시스템에 대한 지속적인 수요가 발생하고 있습니다. 또 다른 중요한 요소는 생명과학 분야의 탈중앙화 추세입니다. 중소기업(SME), 학술 스핀오프 기업, 독립 연구소는 보다 야심찬 프로젝트에 도전하고 있지만, 복잡한 복제 작업을 위한 내부 역량이 부족한 경우가 많아 전문 서비스 제공업체에 의존하는 경우가 많습니다. 개인 맞춤형 의료와 표적 치료를 향한 전 세계적인 움직임도 개별 환자 프로파일과 틈새 적응증에 맞는 맞춤형 유전자 구조에 대한 수요를 촉진하고 있습니다. 또한, 신약 타겟, 효소, 결합 도메인 스크리닝을 위한 합성 유전자 라이브러리 개발은 기존의 연구 용도를 넘어 클로닝 서비스의 유용성을 확장하고 있습니다. 자동화된 하이스루풋 시스템, AI 기반 배열 설계, 고급 벡터 시스템과 같은 기술 인에이블러는 확장성과 신뢰성을 향상시켜 공급자가 복잡한 요구 사항을 가진 더 다양한 고객에게 서비스를 제공할 수 있도록 돕습니다. 마지막으로, 국제 공동연구, 연구비 지원, 정부 지원 유전체 이니셔티브는 분자생물학 인프라에 막대한 자금을 투입하여 지속적인 시장 확대를 위한 비옥한 토양을 조성하고 있습니다. 이러한 종합적인 힘으로 시장의 저변이 확대될 뿐만 아니라 DNA 및 유전자 복제 서비스가 현대 생명과학 혁신의 기본 요소로 확고한 입지를 구축해 나가고 있습니다.
부문
서비스(유전자 합성 서비스, 커스텀 클로닝 서비스, 서브 클로닝 서비스, 기타 서비스), 용도(DNA 시퀀싱 용도, 돌연변이 유발 용도, 유전자형 판정 용도, 기타 용도), 최종 용도(학술기관 및 연구기관 최종 용도, 제약 및 바이오 기업 최종 용도, CMO 및 CRO 최종 용도)
조사 대상 기업 예
abm Inc.(Applied Biological Materials)
ATUM
Bio Basic Inc.
BioCat GmbH
Biolegio B.V.
BioS&T
Blue Heron Biotech
Creative Biogene
Dundee Cell Products
Eurofins Genomics
Eurogentec
GenScript
GENEWIZ from Azenta Life Sciences
Genovac
GenScript Biotech Corporation
Integrated DNA Technologies(IDT)
Invitrogen(Thermo Fisher Scientific)
Macrogen
OriGene Technologies
ProteoGenix
AI 통합
Global Industry Analysts는 유효한 전문가 컨텐츠와 AI툴에 의해서, 시장 정보와 경쟁 정보를 변혁하고 있습니다.
Global Industry Analysts는 일반적인 LLM나 업계별 SLM 쿼리에 따르는 대신에, 비디오 기록, 블로그, 검색 엔진 조사, 대량 기업, 제품/서비스, 시장 데이터 등, 전 세계 전문가로부터 수집한 컨텐츠 리포지토리를 구축했습니다.
관세 영향 계수
Global Industry Analysts는 본사 소재지, 제조거점, 수출입(완제품 및 OEM)을 기준으로 기업의 경쟁력 변화를 예측했습니다. 이러한 복잡하고 다면적인 시장 역학은 수익원가(COGS) 증가, 수익성 하락, 공급망 재편 등 미시적, 거시적 시장 역학 중에서도 특히 경쟁사들에게 영향을 미칠 것으로 예측됩니다.
목차
제1장 조사 방법
제2장 주요 요약
시장 개요
주요 기업
시장 동향과 촉진요인
세계 시장 전망
제3장 시장 분석
미국
캐나다
일본
중국
유럽
프랑스
독일
이탈리아
영국
기타 유럽
아시아태평양
기타 지역
제4장 경쟁
LSH
영문 목차
영문목차
Global DNA and Gene Cloning Services Market to Reach US$7.8 Billion by 2030
The global market for DNA and Gene Cloning Services estimated at US$3.1 Billion in the year 2024, is expected to reach US$7.8 Billion by 2030, growing at a CAGR of 16.5% over the analysis period 2024-2030. Gene Synthesis Service, one of the segments analyzed in the report, is expected to record a 18.0% CAGR and reach US$3.7 Billion by the end of the analysis period. Growth in the Custom Cloning Service segment is estimated at 13.5% CAGR over the analysis period.
The U.S. Market is Estimated at US$822.2 Million While China is Forecast to Grow at 15.4% CAGR
The DNA and Gene Cloning Services market in the U.S. is estimated at US$822.2 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$1.2 Billion by the year 2030 trailing a CAGR of 15.4% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 15.4% and 14.1% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 11.9% CAGR.
Global DNA and Gene Cloning Services Market - Key Trends & Drivers Summarized
Is the Expanding Role of Synthetic Biology Elevating the Demand for Cloning Services?
Synthetic biology has rapidly emerged as a transformative field, driving unprecedented innovation across biotechnology, healthcare, and industrial sectors. At the heart of this movement lies DNA and gene cloning services, which have become essential tools for manipulating genetic material to design novel biological systems and products. The rising demand for custom gene synthesis, vector construction, and plasmid cloning is closely tied to the growing applications of synthetic biology in developing next-generation therapeutics, vaccines, diagnostics, and bio-based materials. In pharmaceutical R&D, gene cloning is used extensively to express therapeutic proteins, study gene function, and engineer disease models. Moreover, in the wake of recent global health challenges, including the COVID-19 pandemic, the importance of rapid genetic engineering for vaccine development has pushed DNA and gene cloning into the spotlight. Cloning services enable researchers to replicate specific DNA sequences with high precision, which is vital for producing recombinant proteins and monoclonal antibodies at scale. The growing collaboration between academic institutions, biotech firms, and contract research organizations (CROs) has led to a steady outsourcing trend, where cloning services are provided by specialized vendors with advanced molecular biology capabilities. These vendors offer integrated solutions-from gene design to expression validation-streamlining research timelines and reducing technical barriers. Additionally, the availability of cloning kits, automation tools, and online design platforms is expanding access to non-specialist labs, democratizing the use of gene editing technologies. The increasing pace of innovation in CRISPR-Cas systems and genome engineering is further accelerating demand for high-fidelity cloning services that support gene knock-ins, knockouts, and mutagenesis studies, making DNA and gene cloning central to the future of bioengineering.
Are Technological Advancements Enhancing the Efficiency and Precision of Cloning Processes?
Technological advancements in molecular biology and genomics are significantly enhancing the efficiency, accuracy, and scalability of DNA and gene cloning services. Traditional methods involving restriction enzymes and ligases have evolved into more sophisticated techniques such as Gibson Assembly, Golden Gate cloning, and site-directed mutagenesis, enabling faster and more seamless DNA assembly. These techniques allow for the precise insertion of genetic sequences into vectors, reducing cloning errors and enabling the construction of complex genetic circuits. Automation is another major game-changer-high-throughput robotic systems now perform repetitive cloning tasks with remarkable speed and reproducibility, allowing service providers to deliver large volumes of customized DNA constructs within short turnaround times. Coupled with real-time PCR and next-generation sequencing (NGS) validation, these systems ensure high-quality control across the cloning workflow. Artificial intelligence is also playing a growing role, particularly in gene sequence optimization for expression in various host organisms, such as E. coli, yeast, or mammalian cells. AI algorithms analyze codon usage, mRNA structure, and GC content to improve translation efficiency and protein yield. Furthermore, innovations in vector design-such as the development of inducible, multi-cloning, and tissue-specific expression systems-have expanded the versatility of gene cloning applications across therapeutic, agricultural, and industrial domains. Cloud-based project management and LIMS platforms now allow seamless communication between clients and service providers, improving transparency, traceability, and data sharing. These technological leaps are not only improving research output but also helping institutions meet rigorous regulatory and quality standards, particularly in clinical and commercial-grade applications of cloned genes. As the demand for precision biotechnology rises, the integration of these cutting-edge tools continues to set new performance benchmarks for DNA and gene cloning services.
Is the Shift Toward Outsourcing and Customization Redefining Service Delivery Models?
As biotechnology and pharmaceutical research becomes increasingly complex and data-driven, organizations are turning to outsourcing as a strategic move to accelerate development timelines and access specialized expertise. DNA and gene cloning services are at the forefront of this outsourcing trend, with companies preferring external partners for tasks such as gene synthesis, vector engineering, expression validation, and library construction. The outsourcing model offers clear advantages: faster project turnaround, access to specialized infrastructure, and cost efficiency-especially for smaller labs and startups with limited in-house capabilities. Leading service providers now offer highly customizable solutions, where clients can specify gene constructs based on length, sequence, tags, expression systems, and even codon optimization preferences. This level of customization is supported by advanced bioinformatics platforms that assist in gene design, error checking, and optimization before synthesis begins. Additionally, services are often bundled with downstream applications such as protein expression, purification, and functional assays, providing end-to-end molecular biology solutions under one roof. There is also a growing emphasis on IP protection and confidentiality, as cloned genetic sequences often represent proprietary information critical to innovation pipelines. Companies are responding by implementing stringent data security protocols, including blockchain-based sample tracking and encrypted sequence delivery. Global expansion of service providers, particularly in Asia-Pacific regions like China and India, is driving cost-effective options without compromising quality, further intensifying competition and innovation. Academic institutions, too, are increasingly partnering with commercial providers to access cloning services at scale for large collaborative projects. This shift in service delivery is not only optimizing research productivity but is also establishing DNA and gene cloning as a critical outsourced utility in the broader life sciences ecosystem.
What Are the Main Growth Accelerators Fueling the DNA and Gene Cloning Services Market?
The growth in the DNA and gene cloning services market is driven by several factors directly linked to technological progression, research diversification, and shifting consumer behavior in biotech and life sciences. One of the primary accelerators is the expanding scope of genetic research in fields such as synthetic biology, immunotherapy, vaccine development, and agricultural biotech, all of which rely heavily on gene cloning to create functional constructs for experimental and therapeutic use. The widespread adoption of gene editing technologies like CRISPR-Cas9 and TALEN has further increased the need for precise cloning services to support genetic modifications, whether for disease modeling or functional gene screening. In parallel, the rise of monoclonal antibodies, cell-based therapies, and recombinant proteins in biopharmaceutical pipelines is generating sustained demand for reliable expression systems constructed through cloning. Another significant factor is the trend toward decentralization in life sciences, where small and mid-sized enterprises (SMEs), academic spin-offs, and independent research labs are taking on more ambitious projects, yet often lack the in-house capabilities for complex cloning tasks-thus turning to specialized service providers. The global movement toward personalized medicine and targeted therapies is also fueling demand for custom gene constructs tailored to individual patient profiles or niche indications. Moreover, the development of synthetic gene libraries for screening drug targets, enzymes, or binding domains is expanding the utility of cloning services beyond traditional research applications. Technological enablers such as automated high-throughput systems, AI-driven sequence design, and advanced vector systems are improving scalability and reliability, allowing providers to serve a more diverse clientele with complex requirements. Finally, international collaborations, research grants, and government-backed genomic initiatives are injecting substantial funding into molecular biology infrastructure, creating fertile ground for sustained market expansion. These collective forces are not only broadening the market base but are solidifying DNA and gene cloning services as a fundamental component of modern bioscience innovation.
SCOPE OF STUDY:
The report analyzes the DNA and Gene Cloning Services market in terms of units by the following Segments, and Geographic Regions/Countries:
Segments:
Service (Gene Synthesis Service, Custom Cloning Service, Sub-cloning Service, Other Services); Application (DNA Sequencing Application, Mutagenesis Application, Genotyping Application, Other Applications); End-Use (Academic & Research Institutes End-Use, Pharma & Biotech Companies End-Use, CMOs & CROs End-Use)
Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.
Select Competitors (Total 42 Featured) -
abm Inc. (Applied Biological Materials)
ATUM
Bio Basic Inc.
BioCat GmbH
Biolegio B.V.
BioS&T
Blue Heron Biotech
Creative Biogene
Dundee Cell Products
Eurofins Genomics
Eurogentec
GenScript
GENEWIZ from Azenta Life Sciences
Genovac
GenScript Biotech Corporation
Integrated DNA Technologies (IDT)
Invitrogen (Thermo Fisher Scientific)
Macrogen
OriGene Technologies
ProteoGenix
AI INTEGRATIONS
We're transforming market and competitive intelligence with validated expert content and AI tools.
Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.
TARIFF IMPACT FACTOR
Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.
TABLE OF CONTENTS
I. METHODOLOGY
II. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
Influencer Market Insights
Tariff Impact on Global Supply Chain Patterns
DNA and Gene Cloning Services - Global Key Competitors Percentage Market Share in 2025 (E)
Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
Boom in Synthetic Biology Research Throws the Spotlight on Scalable DNA and Gene Cloning Solutions
Expanding Use of Gene Cloning in Drug Discovery and Development Propels Growth in Service Demand
Rise of Personalized and Targeted Therapies Strengthens Business Case for Customized Gene Constructs
Proliferation of CRISPR and Genome Editing Applications Drives Adoption of High-Precision Cloning Services
Increasing Outsourcing by Biopharma and Academic Institutions Expands Addressable Market for Specialized Providers
Integration of AI and Bioinformatics in Gene Design Accelerates Demand for Intelligent Cloning Platforms
Growth of Monoclonal Antibody and Recombinant Protein Production Spurs Demand for Expression-Ready Clones
Emergence of High-Throughput and Automated Cloning Workflows Enhances Operational Efficiency and Scalability
Adoption of Cloud-Based Platforms for Sequence Management Drives Digital Transformation in Cloning Services
Surge in Synthetic Gene Library Construction Generates Opportunities in Functional Genomics and Screening
Rising Interest in Rare Disease Research and Orphan Drug Development Spurs Need for Specialized Cloning Capabilities
Expansion of Agri-Biotech and Industrial Biotech Pipelines Propels Demand Beyond Traditional Life Sciences Sectors
Emphasis on Data Security, IP Protection, and Confidentiality Enhances Trust in Third-Party Gene Cloning Services
4. GLOBAL MARKET PERSPECTIVE
TABLE 1: World DNA and Gene Cloning Services Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
TABLE 2: World Recent Past, Current & Future Analysis for DNA and Gene Cloning Services by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 3: World 6-Year Perspective for DNA and Gene Cloning Services by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2025 & 2030
TABLE 4: World Recent Past, Current & Future Analysis for Gene Synthesis Service by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 5: World 6-Year Perspective for Gene Synthesis Service by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
TABLE 6: World Recent Past, Current & Future Analysis for Custom Cloning Service by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 7: World 6-Year Perspective for Custom Cloning Service by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
TABLE 8: World Recent Past, Current & Future Analysis for Sub-cloning Service by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 9: World 6-Year Perspective for Sub-cloning Service by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
TABLE 10: World Recent Past, Current & Future Analysis for Other Services by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 11: World 6-Year Perspective for Other Services by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
TABLE 12: World Recent Past, Current & Future Analysis for Pharma & Biotech Companies End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 13: World 6-Year Perspective for Pharma & Biotech Companies End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
TABLE 14: World Recent Past, Current & Future Analysis for CMOs & CROs End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 15: World 6-Year Perspective for CMOs & CROs End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
TABLE 16: World Recent Past, Current & Future Analysis for Academic & Research Institutes End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 17: World 6-Year Perspective for Academic & Research Institutes End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
TABLE 18: World Recent Past, Current & Future Analysis for DNA Sequencing Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 19: World 6-Year Perspective for DNA Sequencing Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
TABLE 20: World Recent Past, Current & Future Analysis for Mutagenesis Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 21: World 6-Year Perspective for Mutagenesis Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
TABLE 22: World Recent Past, Current & Future Analysis for Genotyping Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 23: World 6-Year Perspective for Genotyping Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
TABLE 24: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 25: World 6-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
III. MARKET ANALYSIS
UNITED STATES
DNA and Gene Cloning Services Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
TABLE 26: USA Recent Past, Current & Future Analysis for DNA and Gene Cloning Services by Service - Gene Synthesis Service, Custom Cloning Service, Sub-cloning Service and Other Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 27: USA 6-Year Perspective for DNA and Gene Cloning Services by Service - Percentage Breakdown of Value Sales for Gene Synthesis Service, Custom Cloning Service, Sub-cloning Service and Other Services for the Years 2025 & 2030
TABLE 28: USA Recent Past, Current & Future Analysis for DNA and Gene Cloning Services by End-Use - Pharma & Biotech Companies End-Use, CMOs & CROs End-Use and Academic & Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 29: USA 6-Year Perspective for DNA and Gene Cloning Services by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, CMOs & CROs End-Use and Academic & Research Institutes End-Use for the Years 2025 & 2030
TABLE 30: USA Recent Past, Current & Future Analysis for DNA and Gene Cloning Services by Application - DNA Sequencing Application, Mutagenesis Application, Genotyping Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 31: USA 6-Year Perspective for DNA and Gene Cloning Services by Application - Percentage Breakdown of Value Sales for DNA Sequencing Application, Mutagenesis Application, Genotyping Application and Other Applications for the Years 2025 & 2030
CANADA
TABLE 32: Canada Recent Past, Current & Future Analysis for DNA and Gene Cloning Services by Service - Gene Synthesis Service, Custom Cloning Service, Sub-cloning Service and Other Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 33: Canada 6-Year Perspective for DNA and Gene Cloning Services by Service - Percentage Breakdown of Value Sales for Gene Synthesis Service, Custom Cloning Service, Sub-cloning Service and Other Services for the Years 2025 & 2030
TABLE 34: Canada Recent Past, Current & Future Analysis for DNA and Gene Cloning Services by End-Use - Pharma & Biotech Companies End-Use, CMOs & CROs End-Use and Academic & Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 35: Canada 6-Year Perspective for DNA and Gene Cloning Services by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, CMOs & CROs End-Use and Academic & Research Institutes End-Use for the Years 2025 & 2030
TABLE 36: Canada Recent Past, Current & Future Analysis for DNA and Gene Cloning Services by Application - DNA Sequencing Application, Mutagenesis Application, Genotyping Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 37: Canada 6-Year Perspective for DNA and Gene Cloning Services by Application - Percentage Breakdown of Value Sales for DNA Sequencing Application, Mutagenesis Application, Genotyping Application and Other Applications for the Years 2025 & 2030
JAPAN
DNA and Gene Cloning Services Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
TABLE 38: Japan Recent Past, Current & Future Analysis for DNA and Gene Cloning Services by Service - Gene Synthesis Service, Custom Cloning Service, Sub-cloning Service and Other Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 39: Japan 6-Year Perspective for DNA and Gene Cloning Services by Service - Percentage Breakdown of Value Sales for Gene Synthesis Service, Custom Cloning Service, Sub-cloning Service and Other Services for the Years 2025 & 2030
TABLE 40: Japan Recent Past, Current & Future Analysis for DNA and Gene Cloning Services by End-Use - Pharma & Biotech Companies End-Use, CMOs & CROs End-Use and Academic & Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 41: Japan 6-Year Perspective for DNA and Gene Cloning Services by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, CMOs & CROs End-Use and Academic & Research Institutes End-Use for the Years 2025 & 2030
TABLE 42: Japan Recent Past, Current & Future Analysis for DNA and Gene Cloning Services by Application - DNA Sequencing Application, Mutagenesis Application, Genotyping Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 43: Japan 6-Year Perspective for DNA and Gene Cloning Services by Application - Percentage Breakdown of Value Sales for DNA Sequencing Application, Mutagenesis Application, Genotyping Application and Other Applications for the Years 2025 & 2030
CHINA
DNA and Gene Cloning Services Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
TABLE 44: China Recent Past, Current & Future Analysis for DNA and Gene Cloning Services by Service - Gene Synthesis Service, Custom Cloning Service, Sub-cloning Service and Other Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 45: China 6-Year Perspective for DNA and Gene Cloning Services by Service - Percentage Breakdown of Value Sales for Gene Synthesis Service, Custom Cloning Service, Sub-cloning Service and Other Services for the Years 2025 & 2030
TABLE 46: China Recent Past, Current & Future Analysis for DNA and Gene Cloning Services by End-Use - Pharma & Biotech Companies End-Use, CMOs & CROs End-Use and Academic & Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 47: China 6-Year Perspective for DNA and Gene Cloning Services by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, CMOs & CROs End-Use and Academic & Research Institutes End-Use for the Years 2025 & 2030
TABLE 48: China Recent Past, Current & Future Analysis for DNA and Gene Cloning Services by Application - DNA Sequencing Application, Mutagenesis Application, Genotyping Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 49: China 6-Year Perspective for DNA and Gene Cloning Services by Application - Percentage Breakdown of Value Sales for DNA Sequencing Application, Mutagenesis Application, Genotyping Application and Other Applications for the Years 2025 & 2030
EUROPE
DNA and Gene Cloning Services Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
TABLE 50: Europe Recent Past, Current & Future Analysis for DNA and Gene Cloning Services by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 51: Europe 6-Year Perspective for DNA and Gene Cloning Services by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2025 & 2030
TABLE 52: Europe Recent Past, Current & Future Analysis for DNA and Gene Cloning Services by Service - Gene Synthesis Service, Custom Cloning Service, Sub-cloning Service and Other Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 53: Europe 6-Year Perspective for DNA and Gene Cloning Services by Service - Percentage Breakdown of Value Sales for Gene Synthesis Service, Custom Cloning Service, Sub-cloning Service and Other Services for the Years 2025 & 2030
TABLE 54: Europe Recent Past, Current & Future Analysis for DNA and Gene Cloning Services by End-Use - Pharma & Biotech Companies End-Use, CMOs & CROs End-Use and Academic & Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 55: Europe 6-Year Perspective for DNA and Gene Cloning Services by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, CMOs & CROs End-Use and Academic & Research Institutes End-Use for the Years 2025 & 2030
TABLE 56: Europe Recent Past, Current & Future Analysis for DNA and Gene Cloning Services by Application - DNA Sequencing Application, Mutagenesis Application, Genotyping Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 57: Europe 6-Year Perspective for DNA and Gene Cloning Services by Application - Percentage Breakdown of Value Sales for DNA Sequencing Application, Mutagenesis Application, Genotyping Application and Other Applications for the Years 2025 & 2030
FRANCE
DNA and Gene Cloning Services Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
TABLE 58: France Recent Past, Current & Future Analysis for DNA and Gene Cloning Services by Service - Gene Synthesis Service, Custom Cloning Service, Sub-cloning Service and Other Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 59: France 6-Year Perspective for DNA and Gene Cloning Services by Service - Percentage Breakdown of Value Sales for Gene Synthesis Service, Custom Cloning Service, Sub-cloning Service and Other Services for the Years 2025 & 2030
TABLE 60: France Recent Past, Current & Future Analysis for DNA and Gene Cloning Services by End-Use - Pharma & Biotech Companies End-Use, CMOs & CROs End-Use and Academic & Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 61: France 6-Year Perspective for DNA and Gene Cloning Services by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, CMOs & CROs End-Use and Academic & Research Institutes End-Use for the Years 2025 & 2030
TABLE 62: France Recent Past, Current & Future Analysis for DNA and Gene Cloning Services by Application - DNA Sequencing Application, Mutagenesis Application, Genotyping Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 63: France 6-Year Perspective for DNA and Gene Cloning Services by Application - Percentage Breakdown of Value Sales for DNA Sequencing Application, Mutagenesis Application, Genotyping Application and Other Applications for the Years 2025 & 2030
GERMANY
DNA and Gene Cloning Services Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
TABLE 64: Germany Recent Past, Current & Future Analysis for DNA and Gene Cloning Services by Service - Gene Synthesis Service, Custom Cloning Service, Sub-cloning Service and Other Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 65: Germany 6-Year Perspective for DNA and Gene Cloning Services by Service - Percentage Breakdown of Value Sales for Gene Synthesis Service, Custom Cloning Service, Sub-cloning Service and Other Services for the Years 2025 & 2030
TABLE 66: Germany Recent Past, Current & Future Analysis for DNA and Gene Cloning Services by End-Use - Pharma & Biotech Companies End-Use, CMOs & CROs End-Use and Academic & Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 67: Germany 6-Year Perspective for DNA and Gene Cloning Services by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, CMOs & CROs End-Use and Academic & Research Institutes End-Use for the Years 2025 & 2030
TABLE 68: Germany Recent Past, Current & Future Analysis for DNA and Gene Cloning Services by Application - DNA Sequencing Application, Mutagenesis Application, Genotyping Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 69: Germany 6-Year Perspective for DNA and Gene Cloning Services by Application - Percentage Breakdown of Value Sales for DNA Sequencing Application, Mutagenesis Application, Genotyping Application and Other Applications for the Years 2025 & 2030
ITALY
TABLE 70: Italy Recent Past, Current & Future Analysis for DNA and Gene Cloning Services by Service - Gene Synthesis Service, Custom Cloning Service, Sub-cloning Service and Other Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 71: Italy 6-Year Perspective for DNA and Gene Cloning Services by Service - Percentage Breakdown of Value Sales for Gene Synthesis Service, Custom Cloning Service, Sub-cloning Service and Other Services for the Years 2025 & 2030
TABLE 72: Italy Recent Past, Current & Future Analysis for DNA and Gene Cloning Services by End-Use - Pharma & Biotech Companies End-Use, CMOs & CROs End-Use and Academic & Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 73: Italy 6-Year Perspective for DNA and Gene Cloning Services by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, CMOs & CROs End-Use and Academic & Research Institutes End-Use for the Years 2025 & 2030
TABLE 74: Italy Recent Past, Current & Future Analysis for DNA and Gene Cloning Services by Application - DNA Sequencing Application, Mutagenesis Application, Genotyping Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 75: Italy 6-Year Perspective for DNA and Gene Cloning Services by Application - Percentage Breakdown of Value Sales for DNA Sequencing Application, Mutagenesis Application, Genotyping Application and Other Applications for the Years 2025 & 2030
UNITED KINGDOM
DNA and Gene Cloning Services Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
TABLE 76: UK Recent Past, Current & Future Analysis for DNA and Gene Cloning Services by Service - Gene Synthesis Service, Custom Cloning Service, Sub-cloning Service and Other Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 77: UK 6-Year Perspective for DNA and Gene Cloning Services by Service - Percentage Breakdown of Value Sales for Gene Synthesis Service, Custom Cloning Service, Sub-cloning Service and Other Services for the Years 2025 & 2030
TABLE 78: UK Recent Past, Current & Future Analysis for DNA and Gene Cloning Services by End-Use - Pharma & Biotech Companies End-Use, CMOs & CROs End-Use and Academic & Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 79: UK 6-Year Perspective for DNA and Gene Cloning Services by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, CMOs & CROs End-Use and Academic & Research Institutes End-Use for the Years 2025 & 2030
TABLE 80: UK Recent Past, Current & Future Analysis for DNA and Gene Cloning Services by Application - DNA Sequencing Application, Mutagenesis Application, Genotyping Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 81: UK 6-Year Perspective for DNA and Gene Cloning Services by Application - Percentage Breakdown of Value Sales for DNA Sequencing Application, Mutagenesis Application, Genotyping Application and Other Applications for the Years 2025 & 2030
REST OF EUROPE
TABLE 82: Rest of Europe Recent Past, Current & Future Analysis for DNA and Gene Cloning Services by Service - Gene Synthesis Service, Custom Cloning Service, Sub-cloning Service and Other Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 83: Rest of Europe 6-Year Perspective for DNA and Gene Cloning Services by Service - Percentage Breakdown of Value Sales for Gene Synthesis Service, Custom Cloning Service, Sub-cloning Service and Other Services for the Years 2025 & 2030
TABLE 84: Rest of Europe Recent Past, Current & Future Analysis for DNA and Gene Cloning Services by End-Use - Pharma & Biotech Companies End-Use, CMOs & CROs End-Use and Academic & Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 85: Rest of Europe 6-Year Perspective for DNA and Gene Cloning Services by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, CMOs & CROs End-Use and Academic & Research Institutes End-Use for the Years 2025 & 2030
TABLE 86: Rest of Europe Recent Past, Current & Future Analysis for DNA and Gene Cloning Services by Application - DNA Sequencing Application, Mutagenesis Application, Genotyping Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 87: Rest of Europe 6-Year Perspective for DNA and Gene Cloning Services by Application - Percentage Breakdown of Value Sales for DNA Sequencing Application, Mutagenesis Application, Genotyping Application and Other Applications for the Years 2025 & 2030
ASIA-PACIFIC
DNA and Gene Cloning Services Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
TABLE 88: Asia-Pacific Recent Past, Current & Future Analysis for DNA and Gene Cloning Services by Service - Gene Synthesis Service, Custom Cloning Service, Sub-cloning Service and Other Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 89: Asia-Pacific 6-Year Perspective for DNA and Gene Cloning Services by Service - Percentage Breakdown of Value Sales for Gene Synthesis Service, Custom Cloning Service, Sub-cloning Service and Other Services for the Years 2025 & 2030
TABLE 90: Asia-Pacific Recent Past, Current & Future Analysis for DNA and Gene Cloning Services by End-Use - Pharma & Biotech Companies End-Use, CMOs & CROs End-Use and Academic & Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 91: Asia-Pacific 6-Year Perspective for DNA and Gene Cloning Services by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, CMOs & CROs End-Use and Academic & Research Institutes End-Use for the Years 2025 & 2030
TABLE 92: Asia-Pacific Recent Past, Current & Future Analysis for DNA and Gene Cloning Services by Application - DNA Sequencing Application, Mutagenesis Application, Genotyping Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 93: Asia-Pacific 6-Year Perspective for DNA and Gene Cloning Services by Application - Percentage Breakdown of Value Sales for DNA Sequencing Application, Mutagenesis Application, Genotyping Application and Other Applications for the Years 2025 & 2030
REST OF WORLD
TABLE 94: Rest of World Recent Past, Current & Future Analysis for DNA and Gene Cloning Services by Service - Gene Synthesis Service, Custom Cloning Service, Sub-cloning Service and Other Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 95: Rest of World 6-Year Perspective for DNA and Gene Cloning Services by Service - Percentage Breakdown of Value Sales for Gene Synthesis Service, Custom Cloning Service, Sub-cloning Service and Other Services for the Years 2025 & 2030
TABLE 96: Rest of World Recent Past, Current & Future Analysis for DNA and Gene Cloning Services by End-Use - Pharma & Biotech Companies End-Use, CMOs & CROs End-Use and Academic & Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 97: Rest of World 6-Year Perspective for DNA and Gene Cloning Services by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, CMOs & CROs End-Use and Academic & Research Institutes End-Use for the Years 2025 & 2030
TABLE 98: Rest of World Recent Past, Current & Future Analysis for DNA and Gene Cloning Services by Application - DNA Sequencing Application, Mutagenesis Application, Genotyping Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 99: Rest of World 6-Year Perspective for DNA and Gene Cloning Services by Application - Percentage Breakdown of Value Sales for DNA Sequencing Application, Mutagenesis Application, Genotyping Application and Other Applications for the Years 2025 & 2030